URGENT PANDEMIC INFORMATION

In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List


2nd Fc Receptor & IgG Targeted Therapies Summit


Date
Apr 26, 2022 - 09:00 AM - Apr 28, 04:00 PM
Organizer
Hanson Wade
Venue
Hilton Boston Back Bay
Location
40 Dalton Street,

Boston,
MA,
US,
ZIP: 02115
Phone:

Ticket Price: USD 2999.00 - USD 4697.00


FcRn, Fcγ, and IgG studies have been propelled by drug developers recently after Argenx’s potential FDA’s approval of first-in-class FcRn antagonist efgartigimod, AstraZeneca-Alexion’s $39 billion deal, and positive clinical updates from UCB’s Rozanolixizumab. Successful modulation of the Fc pathways and optimized IgG antibodies have proven clinical utility and demonstrate significant therapeutic potential with more players poised to bring their candidates through clinic.

The 2nd Fc Receptor & IgG Targeted Therapies Summit is the only dedicated meeting to bring you the most up-to-date with clinical and commercial developments on pioneering strategies to harness the full potential of FcRs.

This 3-day summit will return in 2022 with a fresh speaker line-up, 2 dedicated streams to offer you the A-Z of Fc receptors and IgG targeting. Bringing together exclusive data on targeting FcRn and FcyRs, and the engineering strategies employed to harness the FcR-IgG interaction to yield clinical efficacy. Hear from industry leaders such as FDA, Genentech, Alexion, UCB, Argenx, Genmab, and more as they modulate the dynamic behavior of IgG to fast-track candidates to address unmet medical needs.

Join 130+ experts in Boston to:
- Discuss translating novel Fc biology insights to innovative drug design
- Explore FcR antagonists, Fc fusion proteins, and novel antibodies
- Move confidently to clinic with predictive PKPD assessments from best-in-class cellular assays
- Enhance the therapeutic potential of antibodies with next-gen engineering strategies to minimize immunogenicity

Tickets    https://go.evvnt.com/972245-1?pid=1052
Brochure https://go.evvnt.com/972245-3?pid=1052

Prices:
Conference + 2 Workshops - Pharma Biotech USD 3897.00
Conference Only - Pharma Biotech USD 2999.00
Conference + 2 Workshops - Service provider USD 4697.00
Conference Only - Service provider USD 3599.00

Category: Conferences | Science, Health & Medicine | Pharmaceuticals | Drug Development


Speaker Details


Basil Golding Director FDA/CBER, Hans de Haard Chief Scientific Officer Argenx, Fabian Kasermann Head of Preclinical Innovation CSL Behring, Stefan Zielonka Associate Director – Protein Engineering & Antibody Technologies Merck KGaA, David Humphreys Senior Director & Head of New Modality Therapeutics Protein Sciences UCB, Jennifer Dumont Senior Director Sanofi, Davide Corti Senior Vice President – Antibody Research Vir Bio, Peter Ulrichts Neuromuscular Franchise Scientist Argenx, Anthony Shock Director UCB, Dariush Mohammadyani Senior Scientist Janssen Pharmaceuticals, Karthik Viswanathan Director of Research Visterra, Alyson Smith Associate Director Cancer Target Discovery SeaGen, Rob de Jong Director – Antibody Research & Technology Genmab, Bram Estes Senior Scientist Amgen, Rolf Spring Deputy Head Preclinical Innovation CSL Behring, Jou-Ku Chung Head of Clinical Pharmacology & Translational Medicine Astria Therapeutics, Lu Shan Associate Director of Antibody Discovery & Engineering Denali Therapeutics, Chang Liu Associate Scientist Genentech, Julian Chandler Research Scientist III Alexion Pharmaceuticals, Eric Escobar Cabrera Cabrera Principal Scientist Zymeworks Inc, Brian Rabinovich Co-Founder & Chief Scientific Officer Fuse Biotherapeutics, Tilman Schlothauer Senior Principal Scientist, Matrix Lead Roche Innovation Center Roche Innovation Center, Martin Siegemund Senior Researcher Pieris, Sally Ward Director of Translational Immunology University of Southampton, Jan Terje Andersen Professor – Biomedical Innovation University of Oslo, Harald Kolmer Head of Department Technical University Darmstadt, Jeanette Leusen Head of Immunotherapy Lab University Medical Centre Utrecht, Kenneth Howard Associate Professor Interdisciplinary Nanoscience Center Aarhus University

Event Categories
Keywords: immunogenicit




Comments








Events Calendar

SunMonTueWedThuFriSat
27 28 29 30 31 1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Newsletters

VIP Life Time Subscription to our Newsletters!
$399.99
$299.99